An investor angle arguing Lilly's triple agonist could become a bigger growth driver than Zepbound, ahead of the company's quarterly report.
Recap by typeshit. Full story at The Motley Fool on MSN.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
Philstar Life looks at famous names linked to Ozempic for weight loss. Only a search title came through, so details are thin until you open the source.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
KFF Health News
Users describe migraines, eye pain and fatigue, while an FDA panel stacked with industry-tied doctors voted to ease limits on six unapproved peptides.
Becker's cites FDA and Eli Lilly reports on the deaths, which add to concerns over illicit versions of the unapproved weight loss drug.
Loading…